Summit Therapeutics (SMMT) to Release Earnings on Wednesday

Summit Therapeutics (NASDAQ:SMMT) will release its earnings data before the market opens on Wednesday, December 6th. Analysts expect Summit Therapeutics to post earnings of ($0.73) per share for the quarter.

Shares of Summit Therapeutics (SMMT) traded up $0.34 during mid-day trading on Tuesday, reaching $12.02. 9,100 shares of the company’s stock traded hands, compared to its average volume of 22,156. Summit Therapeutics has a one year low of $7.95 and a one year high of $16.86.

Several brokerages have weighed in on SMMT. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Summit Therapeutics in a research note on Friday. Zacks Investment Research raised shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Canaccord Genuity reissued a “buy” rating on shares of Summit Therapeutics in a research report on Monday, October 16th. Oppenheimer reissued a “buy” rating and set a $24.00 price target on shares of Summit Therapeutics in a research report on Monday, October 16th. Finally, ValuEngine cut shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $20.25.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.chaffeybreeze.com/2017/12/05/summit-therapeutics-smmt-to-release-earnings-on-wednesday.html.

About Summit Therapeutics

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply